A NOVEL PHASE II TRIAL OF IPILIMUMAB, CARBOPLATIN AND ETOPOSIDE (ICE) FOR THE FIRST LINE TREATMENT OF EXTENSIVE STAGE SMALL CELL LUNG CANCER (SCLC)

被引：2

作者：

Ottensmeier, C. ^{[1
]}

Galea, I. ^{[2
]}

Cross, N. ^{[3
]}

Maishman, T. ^{[3
]}

Hamid, D. ^{[3
]}

Cave, J. ^{[4
]}

Wheater, M. ^{[5
]}

Geldart, T. ^{[6
]}

Mulatero, C. ^{[7
]}

Potter, V. ^{[8
]}

Danson, S. ^{[9
]}

Woll, P. ^{[10
]}

Griffiths, R. ^{[11
]}

Nolan, L. ^{[5
]}

机构：

[1] Southampton Univ Hosp NHS Trust, Canc Sci Div, Southampton, Hants, England

[2] Univ Hosp Southampton NHS Fdn Trust, Wessex Neurosci Ctr, Southampton, Hants, England

[3] Univ Southampton, Clin Trials Unit, Southampton, Hants, England

[4] Univ Hosp Southampton NHS FoundationTrust, Dept Med Oncol, Southampton, Hants, England

[5] Univ Hosp Southampton NHS Fdn Trust, Southampton, Hants, England

[6] Royal Bournemouth Hosp, Bournemouth, Dorset, England

[7] Leeds Teaching Hosp NHS Trust, St James Univ Hosp, Leeds, W Yorkshire, England

[8] Nottingham Univ Hosp NHS Trust, Dept Oncol, Nottingham, England

[9] Weston Pk Hosp, Canc Res Ctr, Acad Unit Clin Oncol, Sheffield, S Yorkshire, England

[10] Weston Pk Hosp, Canc Res Ctr, Dept Oncol, Sheffield, S Yorkshire, England

[11] Clatterbridge Canc Ctr, Wirral, Merseyside, England

来源：

ANNALS OF ONCOLOGY | 2014年 / 25卷

关键词：

D O I：

10.1093/annonc/mdu355.15

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1477P

引用

下载

页数：1

共 50 条

[21] Paclitaxel, carboplatin, and oral etoposide: A phase II trial in limited-stage small cell lung cancer
Gatzemeier, U
Jagos, U
Kaukel, E
Koschel, G
vonPawel, J
SEMINARS IN ONCOLOGY, 1997, 24 (04) : 149 - 152
[22] Phase II Trial of Irinotecan, Carboplatin, and Bevacizumab in the Treatment of Patients with Extensive-Stage Small-Cell Lung Cancer
Spigel, David R.
Greco, F. Anthony
Zubkus, John D.
Murphy, Patrick B.
Saez, Ruben A.
Farley, Cindy
Yardley, Denise A.
Burris, Howard A., III
Hainsworth, John D.
JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (12) : 1555 - 1560
[23] Phase II study of irinotecan and carboplatin followed by maintenance sunitinib in the first-line treatment of extensive-stage small cell lung cancer
Lubiner, E. T.
Spigel, D. R.
Greco, F. A.
Rubin, M. S.
Shipley, D.
Thompson, D. S.
Eakle, J. F.
Brown, R. H.
Burris, H. A., III
Hainsworth, J. D.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[24] Phase II Study of Roniciclib in Combination with Cisplatin/Etoposide or Carboplatin/Etoposide as First-Line Therapy in Patients with Extensive-Disease Small Cell Lung Cancer
Reck, Martin
Horn, Leora
Novello, Silvia
Barlesi, Fabrice
Albert, Istvan
Juhasz, Erzsebet
Kowalski, Dariusz
Robinet, Gilles
Cadranel, Jacques
Bidoli, Paolo
Chung, John
Fritsch, Arno
Drews, Uta
Wagner, Andrea
Govindan, Ramaswamy
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (04) : 701 - 711
[25] Phase II trial of irinotecan, carboplatin, and bevacizumab in patients with extensive-stage small cell lung cancer
Spigel, D. R.
Hainsworth, J. D.
Yardley, D. A.
Burris, H. A., III
Farley, C.
Zubkus, J.
Meng, C.
Murphy, P.
Saez, R.
Greco, F. A.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[26] Randomized phase II study of carboplatin and etoposide with or without obatoclax mesylate in extensive-stage small cell lung cancer
Langer, Corey J.
Albert, Istvan
Ross, Helen J.
Kovacs, Peter
Blakely, L. Johnetta
Pajkos, Gabor
Somfay, Attila
Zatloukal, Petr
Kazarnowicz, Andrzei
Moezi, Mehdi M.
Schreeder, Marshall T.
Schnyder, Judy
Ao-Baslock, Ada
Pathak, Ashutosh K.
Berger, Mark S.
LUNG CANCER, 2014, 85 (03) : 420 - 428
[27] A phase II study of carboplatin, etoposide and exisulind in patients with extensive stage small cell lung cancer: CALGB 30104.
Wang, XF
Govindan, R
Herndon, JE
Barrier, RC
Watson, D
Vokes, RFEE
Green, MR
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 660S - 660S
[28] A randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin in patients with extensive disease small cell lung cancer
Schmittel, A.
Fischer von Weikersthal, L.
Sebastian, M.
Schulze, K.
Link, H.
Thiel, E.
Keilholz, U.
EJC SUPPLEMENTS, 2005, 3 (02): : 327 - 328
[29] Triplet combination of carboplatin, irinotecan, and etoposide in the first-line treatment of extensive small-cell lung cancer: a single-institution phase II study
Charpidou, Andriani
Tsagouli, Sophia
Tsimpoukis, Sotirios
Vassias, Antonios
Makrilia, Nektaria
Stratakos, Grigorios
Gkiozos, Ioannis
Syrigos, Kostas
ANTI-CANCER DRUGS, 2010, 21 (06) : 651 - 655
[30] KEYNOTE-604: Phase 3 trial of pembrolizumab plus etoposide/platinum (EP) for first-line treatment of extensive stage small-cell lung cancer (ES-SCLC)
Rudin, C. M.
Shen, L.
Pietanza, M. C.
ANNALS OF ONCOLOGY, 2017, 28

← 1 2 3 4 5 →